ClinicalTrials.gg
CompletedNCT05699369Updated Sep 29, 2026

Interventions to Improve Non-communicable Disease Management During the Pandemic

An interventional study of Digital health interventions in Noncommunicable Diseases and COVID-19, sponsored by University of Toronto. Completed at 1 site in Pakistan. Open to participants aged 25 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by University of Toronto · Not applicable, Interventional, and Health services research

How we know

Updated Sep 29, 2026Now CompletedStart date moved+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,965
Allocation
Randomized
Ages
25 Years and older
Sex
All
01

Study summary

This randomized controlled trial aims to implement and evaluate a comprehensive package of digital health interventions for integrated COVID-non-communicable diseases (NCDs) care to manage NCDs in primary care facilities in rural Pakistan. The main questions it aims to answer are 1) whether such interventions are effective; 2) how they were implemented; and 3) whether such interventions are cost-effective.

30 rural health centers in Punjab Province, Pakistan will be randomized into two groups. The intervention group will provide a comprehensive package of digital health interventions to connect patients, patient champions, and public health providers to improve the management of NCDs during the pandemic, including 1) providing training to health providers regarding an integrated NCD-COVID guideline; 2) using a smartphone app to improve NCD case management and linking with patient champions; and 3) employing telementoring platform to improve quality of care. Usual care will be provided in the control group. Researchers will compare the two groups to see if the systolic blood pressure can be controlled better in the intervention group at 12 months.

02

Conditions studied

  • Noncommunicable Diseases
  • COVID-19

Keywords

  • digital health interventions
  • non-communicable diseases
  • cluster randomised trial
  • implementation science
  • resilience
  • Pakistan
03

In context

Noncommunicable Diseases

146 studies on the registry are indexed under Noncommunicable Diseases; 57 are open to participants now.

This study's enrollment of 1,965 is above the median of 478 across 97 interventional studies indexed under Noncommunicable Diseases.

Browse Noncommunicable Diseases studies →

Lead sponsor

University of Toronto is the lead sponsor of 405 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Reside in the catchment of selected rural health centers;
  • Provide ;
  • Newly diagnosed of hypertension, i.e., having a baseline blood pressure reading (recorded from the second blood pressure reading using a validated electronic blood pressure machine) of more than 140/90 mmHg; or who is an existing hypertensive patient but with uncontrolled blood pressure with a baseline blood pressure over 140/90 mmHg;
  • Have a smartphone or can access a smartphone from a relative.

Exclusion criteria

Exclusion Criteria:

  • Patients having an acute cardiovascular event in the last three months, terminal disease, or other conditions that the rural health center staff determine that will make participation impossible.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,965 participants (actual)

Study arms

  • Experimental
    Intervention arm

    A comprehensive package of digital health interventions to connect patients, patient champions and public health providers to improve the management of non-communicable diseases (NCDs) during the pandemic will be implemented, including 1) providing training to health providers regarding an integrated NCD-COVID guideline; 2) using a smartphone app to improve NCD case management and linking with patient champions; and 3) employing telementoring platform to improve quality of care. Patient champions are experienced patients who can provide peer support.

    Other: Digital health interventions

  • No intervention
    Control arm

    Usual care, which is routine hypertension and diabetes diagnosis and treatment under the World Diabetes Foundation (WDF) project will be implemented. The WDF project provides initial Zoom-based training of NCD care to rural health center (RHC) staff, but no tele-mentorship is offered. Under the usual care, patients with hypertension or diabetes are required to visit RHCs every month to renew their medications and measure their blood pressure. No other interventional components will be implemented in the control arm.

Interventions

  • OtherDigital health interventions

    Described in arm descriptions.

06

What researchers measure

Primary outcomes

  1. Systolic blood pressure (mmHg) measured in the rural health center

    Following the Trial Steering Committee's decision in October 2023, the intervention period was extended from 10 to 12 months; consequently, the timing of the outcome measure was rescheduled to Month 12.

    Time frame: At 12 months

Secondary outcomes

  1. Diastolic blood pressure (mmHg) measured in the rural health center

    Following the Trial Steering Committee's decision in October 2023, the intervention period was extended from 10 to 12 months; consequently, the timing of the outcome measure was rescheduled to Month 12.

    Time frame: At 12 months

  2. Percentage of patients with controlled blood pressure measured below 140/90 mmHg for patients with hypertension but without diabetes, and below 130/80 mmHg for patients with diabetes

    Following the Trial Steering Committee's decision in October 2023, the intervention period was extended from 10 to 12 months; consequently, the timing of the outcome measure was rescheduled to Month 12.

    Time frame: At 12 months

  3. Random blood glucose (mmol/L)

    Following the Trial Steering Committee's decision in October 2023, the intervention period was extended from 10 to 12 months; consequently, the timing of the outcome measure was rescheduled to Month 12.

    Time frame: At 12 months

  4. Body mass index (BMI)

    Following the Trial Steering Committee's decision in October 2023, the intervention period was extended from 10 to 12 months; consequently, the timing of the outcome measure was rescheduled to Month 12.

    Time frame: At 12 months

  5. Number of consultations with RHC doctors, including both in-person and virtual consultations

    Following the Trial Steering Committee's decision in October 2023, the intervention period was extended from 10 to 12 months.

    Time frame: During the 12-month intervention period

  6. Systolic and diastolic blood pressure

    Time frame: At 6 months

  7. Proportion of patients who have had at least three doses of COVID vaccinations

    Following the Trial Steering Committee's decision in October 2023, the intervention period was extended from 10 to 12 months; consequently, the timing of the outcome measure was rescheduled to Month 12.

    Time frame: At 12 months

  8. Proportion of participants been admitted to district hospitals for any reasons

    Following the Trial Steering Committee's decision in October 2023, the intervention period was extended from 10 to 12 months.

    Time frame: During the 12-month intervention period

  9. All-cause mortality rate

    Following the Trial Steering Committee's decision in October 2023, the intervention period was extended from 10 to 12 months.

    Time frame: During the 12-month intervention period

07

Study locations

1 site
  • Primary care facilities
    Sargodha, Punjab Province, Pakistan
08

References and documents

Publications

  • Wei X, Khan N, Durrani H, Muzaffar N, Haldane V, Walley JD, Thorpe K, Ge E, Ge S, Dodd W, Wallace J, Aslanyan G, Laporte A, Khan MA. Protocol for a pragmatic cluster randomised controlled trial to evaluate the effectiveness of digital health interventions in improving non-communicable disease management during the pandemic in rural Pakistan. PLoS One. 2023 Oct 10;18(10):e0282543. doi: 10.1371/journal.pone.0282543. eCollection 2023. PubMed 37816010 ↗

Individual participant data

Plan to share: Yes — According to the ethical agreements, the data is only available for research purpose of the study team. Individual patient data cannot be posted and downloaded in a public data depository. Anonymous data can be shared upon request to the study contacts with joint ethics application to the University of Toronto.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After publication in peer-reviewed journals.

Access criteria: The research team will aim to publish them in open access journals as priority so that all other researchers will freely access to them.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in May 2024, 15 months.

Of 79 non-industry interventional studies with no phase under Noncommunicable Diseases, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's 15 months is below that.

Counting every sponsor, half of 79 studies reached it within 17 months; a quarter within 7 and three quarters within 30.

Noncommunicable Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: start Jan 2023 → Feb 2023, primary completion Feb 2024 → May 2024 and completion Feb 2024 → Aug 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2023
First posted
Jan 26, 2023
StartActual
Feb 1, 2023was Jan 2023
Primary completionActual
May 31, 2024was Feb 2024
CompletionActual
Aug 31, 2024was Feb 2024
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Sep 29, 2026
Sites
1 site added, 1 site removed
Show site
  • Primary care facilities · Sargodha, Pakistan
Show 1 removed
  • Primary care facilities · Sargodha, Pakistan
Sep 29, 2026
Start date
Jan 25, 2023→Feb 1, 2023
Sep 29, 2026
Primary completion
Feb 15, 2024→May 31, 2024 (actual)
Sep 29, 2026
Study completion
Feb 15, 2024→Aug 31, 2024 (actual)
Sep 29, 2026
Enrollment
1500 (estimated)→1965 (actual)
Sep 29, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameSystolic blood pressure (mmHg) measured in the rural health centerAt 10 months → At 12 months
  • DescriptionSystolic blood pressure (mmHg) measured in the rural health center: how it is measured was reworded
Sep 29, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 37816010 ↗
Sep 29, 2026
Secondary outcomes
8 time frame changed, 8 description edited
What changed in the outcomes
  • Time frameDiastolic blood pressure (mmHg) measured in the rural health centerAt 10 months → At 12 months
  • Time framePercentage of patients with controlled blood pressure measured below 140/90 mmHg for patients with hypertension but without diabetes, and below 130/80 mmHg for patients with diabetesAt 10 months → At 12 months
  • Time frameRandom blood glucose (mmol/L)At 10 months → At 12 months
  • Time frameBody mass index (BMI)At 10 months → At 12 months
  • Time frameNumber of consultations with RHC doctors, including both in-person and virtual consultationsDuring the 10-month intervention period → During the 12-month intervention period
  • Time frameProportion of patients who have had at least three doses of COVID vaccinationsAt 10 months → At 12 months
  • Time frameProportion of participants been admitted to district hospitals for any reasonsDuring the 10-month intervention period → During the 12-month intervention period
  • Time frameAll-cause mortality rateDuring the 10-month intervention period → During the 12-month intervention period
  • DescriptionAll-cause mortality rate: how it is measured was reworded
  • DescriptionBody mass index (BMI): how it is measured was reworded
  • DescriptionDiastolic blood pressure (mmHg) measured in the rural health center: how it is measured was reworded
  • DescriptionNumber of consultations with RHC doctors, including both in-person and virtual consultations: how it is measured was reworded
  • DescriptionPercentage of patients with controlled blood pressure measured below 140/90 mmHg for patients with hypertension but without diabetes, and below 130/80 mmHg for patients with diabetes: how it is measured was reworded
  • DescriptionProportion of participants been admitted to district hospitals for any reasons: how it is measured was reworded
  • DescriptionProportion of patients who have had at least three doses of COVID vaccinations: how it is measured was reworded
  • DescriptionRandom blood glucose (mmol/L): how it is measured was reworded
Sep 29, 2026
Sponsor
Collaborators added: Canadian Institutes of Health Research (CIHR); collaborators removed: Canadian Institutes of Health Reesearch
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Recruiting→Completed
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 37816010 ↗
    1 site added, 1 site removed
    Show site
    • Primary care facilities · Sargodha, Pakistan
    Show 1 removed
    • Primary care facilities · Sargodha, Pakistan
    Start date Jan 25, 2023→Feb 1, 2023
    Primary completion Feb 15, 2024→May 31, 2024 (now actual)
    Study completion Feb 15, 2024→Aug 31, 2024 (now actual)
    Enrollment 1500 (estimated)→1965 (actual)
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameSystolic blood pressure (mmHg) measured in the rural health centerAt 10 months → At 12 months
    • DescriptionSystolic blood pressure (mmHg) measured in the rural health center: how it is measured was reworded
    Secondary outcomes 8 time frame changed, 8 description edited
    What changed in the outcomes
    • Time frameDiastolic blood pressure (mmHg) measured in the rural health centerAt 10 months → At 12 months
    • Time framePercentage of patients with controlled blood pressure measured below 140/90 mmHg for patients with hypertension but without diabetes, and below 130/80 mmHg for patients with diabetesAt 10 months → At 12 months
    • Time frameRandom blood glucose (mmol/L)At 10 months → At 12 months
    • Time frameBody mass index (BMI)At 10 months → At 12 months
    • Time frameNumber of consultations with RHC doctors, including both in-person and virtual consultationsDuring the 10-month intervention period → During the 12-month intervention period
    • Time frameProportion of patients who have had at least three doses of COVID vaccinationsAt 10 months → At 12 months
    • Time frameProportion of participants been admitted to district hospitals for any reasonsDuring the 10-month intervention period → During the 12-month intervention period
    • Time frameAll-cause mortality rateDuring the 10-month intervention period → During the 12-month intervention period
    • DescriptionAll-cause mortality rate: how it is measured was reworded
    • DescriptionBody mass index (BMI): how it is measured was reworded
    • DescriptionDiastolic blood pressure (mmHg) measured in the rural health center: how it is measured was reworded
    • DescriptionNumber of consultations with RHC doctors, including both in-person and virtual consultations: how it is measured was reworded
    • DescriptionPercentage of patients with controlled blood pressure measured below 140/90 mmHg for patients with hypertension but without diabetes, and below 130/80 mmHg for patients with diabetes: how it is measured was reworded
    • DescriptionProportion of participants been admitted to district hospitals for any reasons: how it is measured was reworded
    • DescriptionProportion of patients who have had at least three doses of COVID vaccinations: how it is measured was reworded
    • DescriptionRandom blood glucose (mmol/L): how it is measured was reworded
    Sponsor Collaborators added: Canadian Institutes of Health Research (CIHR); collaborators removed: Canadian Institutes of Health Reesearch
    + 4 other changes: verification date, description, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05699369
Collaborators
Canadian Institutes of Health Research (CIHR), Association for Social Development, Pakistan
Responsible party
Xiaolin Wei (Professor, University of Toronto) — Principal investigator
First posted
Jan 26, 2023
Start date
Feb 1, 2023
Primary completion
May 31, 2024
Completion
Aug 31, 2024
Last update
Sep 29, 2026

Study contacts

Xiaolin Wei, PhD
principal investigator · University of Toronto

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion